Menopause – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Menopause Market Outlook

Thelansis’s “Menopause Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Menopause treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Menopause Overview

Menopause, a natural process in aging women, involves permanently ceasing menstrual periods for 12 months. A deficiency in estrogen causes this cessation and is not linked to any pathological condition. As women age, the number of ovarian follicles they possess decreases. The decline in granulosa cells, the primary producers of estradiol and inhibin, occurs in the ovary. This reduction leads to an absence of inhibition on gonadotropins, resulting in elevated production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The increase in FSH levels tends to be more pronounced than LH due to LH’s faster clearance from the bloodstream. The decrease in estrogen levels disrupts the hypothalamic-pituitary-ovarian axis, leading to a lack of endometrial development. Consequently, menstrual cycles become irregular before eventually ceasing altogether. It can be induced by surgical procedures like a hysterectomy with bilateral oophorectomy or by treatments for certain medical conditions such as endometriosis, breast cancer (using antiestrogens), and other cancers (due to chemotherapy medications). After menopause, the most prominent symptoms include genitourinary issues like vulvovaginal atrophy, dryness, and lower urinary tract problems such as urinary frequency, urgency, and nocturia. The core criteria for identifying menopause rely on the menstrual cycle, supported by laboratory tests. The female reproductive cycle is categorized into three phases: reproductive, menopause transition, and post-menopause. If left untreated, vasomotor symptoms usually fade after an average period of about 7.4 years.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Menopause – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034